PharmaCyte Biotech, Inc. (PMCB): Nasdaq/NYSE listing notice — PharmaCyte Biotech receives Nasdaq notice of non-compliance with $1.00 minimum bid price

PharmaCyte Biotech, Inc.

Notice received Dec 1, 2025; stock closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until June 1, 2026, to regain compliance.
To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.
If not cured by June 1, 2026, Company may seek a second 180-day period or face delisting.
Options under consideration include a reverse stock split, subject to stockholder approval.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

PharmaCyte Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A), 5810(c)(3)(H)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A), 5810(c)(3)(H)

Exact text from the filing

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until June 1, 2026 (the “Compliance Date”), to regain compliance

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PharmaCyte Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-25-008947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.